Effective treatment of acute-on-chronic liver failure (ACLF) is an immediate and unmet requirement. The A-TANGO consortium tests and examines an ingenious brand-new treatment that intends to minimize swelling and enhance hepatocyte expansion by repurposing TAK-242, a villain of toll-like receptor 4, in mix with G-CSF (granulocyte colony-stimulating element). We call this unique combinatorial treatment G-TAK. In addition, A-TANGO aims to recognize trustworthy biomarkers for much better client stratification and an increased survival rate.
Watch this video of Daniel Green – A-TANGO job partner, business owner, and CEO of Yaqrit ( https://yaqrit.com) – holding an interactive and enjoyable Masterclass on #medicaldevices style, #biotechnology, and #entrepreneurship. The Masterclass was tape-recorded as part of the early-career researchers (ECS) program throughout the 2nd A-TANGO General Assembly (GA) Meeting in Barcelona, Spain, on 11 May2022
This job has actually gotten financing from the European Union’s Horizon 2020 research study and development program under grant contract No945096 This video shows just the speaker’s view and the European Commission is not accountable for any usage that might be made from the details it includes.
Production: Tassilo Steinmann and Dr. Nina Donner
Subtitles: Nicolas Lupke
https://concentris.de
© 2022 A-TANGO
http://medicaltranscriptionprograms.com/a-tango-masterclass-2022-medical-device-design-biotechnology-and-entrepreneurship-daniel-green/
No comments:
Post a Comment